Approval · Notice of Compliance 26737 · 2021
BOSULIF: Notice of Compliance 26737
Issued September 24, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26737
- Date
- September 24, 2021
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of an alternate manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BOSULIF | Not yet assigned | — |
Medicinal ingredients
- BOSUTINIB MONOHYDRATE 100 MG per TAB
- BOSUTINIB MONOHYDRATE 400 MG per TAB
- BOSUTINIB MONOHYDRATE 500 MG per TAB